Switching from branded to generic inhaled medications

potential impact on asthma and COPD

Federico Lavorini, Vincent Ninane, John Haughney, Leif Bjermer, Mathieu Molimard, Richard Pn Dekhuijzen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Pressure on healthcare budgets is increasing, while at the same time patent protection for many branded inhaled medications has expired, leading to the development and growing availability of generic inhaled medicines. Generic inhaled drugs are therapeutically equivalent to original branded options but may differ in their formulation and inhalation device. This new situation raises questions about the potential impact of switching from branded to generic drug/inhaler combination products in patients with asthma or COPD, with or without their consent, in countries where this is permitted. Inhalation devices, particularly dry powder inhalers, vary markedly in their design, method of operation and drug delivery to the lungs. Current guidelines stress the importance of training patients how to use their inhalers but offer little or no guidance on how this should be achieved. Non-adherence to therapy and incorrect inhaler usage are recognised as major factors in poorly or uncontrolled asthma and COPD and switching patients to a different inhaler device may exacerbate these problems, particularly in patients who disagree to switch. Where switching is permitted or mandatory, adequate patient instruction and follow-up monitoring should be provided routinely.

Original languageEnglish
Pages (from-to)1597-602
Number of pages6
JournalExpert Opinion on Drug Delivery
Volume10
Issue number12
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Nebulizers and Vaporizers
Chronic Obstructive Pulmonary Disease
Asthma
Generic Drugs
Dry Powder Inhalers
Budgets
Drug Combinations
Guidelines
Delivery of Health Care
Pressure
Equipment and Supplies
Lung
Pharmaceutical Preparations

Keywords

  • Administration, Inhalation
  • Asthma
  • Drug Substitution
  • Drugs, Generic
  • Europe
  • Humans
  • Legislation, Drug
  • Nebulizers and Vaporizers
  • Pulmonary Disease, Chronic Obstructive
  • United States
  • United States Food and Drug Administration

Cite this

Switching from branded to generic inhaled medications : potential impact on asthma and COPD. / Lavorini, Federico; Ninane, Vincent; Haughney, John; Bjermer, Leif; Molimard, Mathieu; Dekhuijzen, Richard Pn.

In: Expert Opinion on Drug Delivery, Vol. 10, No. 12, 12.2013, p. 1597-602.

Research output: Contribution to journalArticle

Lavorini, Federico ; Ninane, Vincent ; Haughney, John ; Bjermer, Leif ; Molimard, Mathieu ; Dekhuijzen, Richard Pn. / Switching from branded to generic inhaled medications : potential impact on asthma and COPD. In: Expert Opinion on Drug Delivery. 2013 ; Vol. 10, No. 12. pp. 1597-602.
@article{097b0c90607d4a88934232c29fe6f45f,
title = "Switching from branded to generic inhaled medications: potential impact on asthma and COPD",
abstract = "Pressure on healthcare budgets is increasing, while at the same time patent protection for many branded inhaled medications has expired, leading to the development and growing availability of generic inhaled medicines. Generic inhaled drugs are therapeutically equivalent to original branded options but may differ in their formulation and inhalation device. This new situation raises questions about the potential impact of switching from branded to generic drug/inhaler combination products in patients with asthma or COPD, with or without their consent, in countries where this is permitted. Inhalation devices, particularly dry powder inhalers, vary markedly in their design, method of operation and drug delivery to the lungs. Current guidelines stress the importance of training patients how to use their inhalers but offer little or no guidance on how this should be achieved. Non-adherence to therapy and incorrect inhaler usage are recognised as major factors in poorly or uncontrolled asthma and COPD and switching patients to a different inhaler device may exacerbate these problems, particularly in patients who disagree to switch. Where switching is permitted or mandatory, adequate patient instruction and follow-up monitoring should be provided routinely.",
keywords = "Administration, Inhalation, Asthma, Drug Substitution, Drugs, Generic, Europe, Humans, Legislation, Drug, Nebulizers and Vaporizers, Pulmonary Disease, Chronic Obstructive, United States, United States Food and Drug Administration",
author = "Federico Lavorini and Vincent Ninane and John Haughney and Leif Bjermer and Mathieu Molimard and Dekhuijzen, {Richard Pn}",
year = "2013",
month = "12",
doi = "10.1517/17425247.2013.852182",
language = "English",
volume = "10",
pages = "1597--602",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Taylor & Francis",
number = "12",

}

TY - JOUR

T1 - Switching from branded to generic inhaled medications

T2 - potential impact on asthma and COPD

AU - Lavorini, Federico

AU - Ninane, Vincent

AU - Haughney, John

AU - Bjermer, Leif

AU - Molimard, Mathieu

AU - Dekhuijzen, Richard Pn

PY - 2013/12

Y1 - 2013/12

N2 - Pressure on healthcare budgets is increasing, while at the same time patent protection for many branded inhaled medications has expired, leading to the development and growing availability of generic inhaled medicines. Generic inhaled drugs are therapeutically equivalent to original branded options but may differ in their formulation and inhalation device. This new situation raises questions about the potential impact of switching from branded to generic drug/inhaler combination products in patients with asthma or COPD, with or without their consent, in countries where this is permitted. Inhalation devices, particularly dry powder inhalers, vary markedly in their design, method of operation and drug delivery to the lungs. Current guidelines stress the importance of training patients how to use their inhalers but offer little or no guidance on how this should be achieved. Non-adherence to therapy and incorrect inhaler usage are recognised as major factors in poorly or uncontrolled asthma and COPD and switching patients to a different inhaler device may exacerbate these problems, particularly in patients who disagree to switch. Where switching is permitted or mandatory, adequate patient instruction and follow-up monitoring should be provided routinely.

AB - Pressure on healthcare budgets is increasing, while at the same time patent protection for many branded inhaled medications has expired, leading to the development and growing availability of generic inhaled medicines. Generic inhaled drugs are therapeutically equivalent to original branded options but may differ in their formulation and inhalation device. This new situation raises questions about the potential impact of switching from branded to generic drug/inhaler combination products in patients with asthma or COPD, with or without their consent, in countries where this is permitted. Inhalation devices, particularly dry powder inhalers, vary markedly in their design, method of operation and drug delivery to the lungs. Current guidelines stress the importance of training patients how to use their inhalers but offer little or no guidance on how this should be achieved. Non-adherence to therapy and incorrect inhaler usage are recognised as major factors in poorly or uncontrolled asthma and COPD and switching patients to a different inhaler device may exacerbate these problems, particularly in patients who disagree to switch. Where switching is permitted or mandatory, adequate patient instruction and follow-up monitoring should be provided routinely.

KW - Administration, Inhalation

KW - Asthma

KW - Drug Substitution

KW - Drugs, Generic

KW - Europe

KW - Humans

KW - Legislation, Drug

KW - Nebulizers and Vaporizers

KW - Pulmonary Disease, Chronic Obstructive

KW - United States

KW - United States Food and Drug Administration

U2 - 10.1517/17425247.2013.852182

DO - 10.1517/17425247.2013.852182

M3 - Article

VL - 10

SP - 1597

EP - 1602

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 12

ER -